1 Min Read
May 22 (Reuters) - Pfizer Inc:
* PFIZER BEGINS A PHASE 1/2 STUDY TO EVALUATE RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.